Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$253.26
+0.5%		$254.21
$186.05
▼
$282.15
$15.81B0.39679,422 shs75,525 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$80.84
-0.3%		$79.11
$47.26
▼
$93.42
$15.82B0.962.95 million shs272,101 shs
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$66.35
+2.0%		$60.85
$49.26
▼
$70.98
$12.84B0.242.07 million shs215,108 shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$11.67
-0.1%		$11.01
$6.28
▼
$12.58
$3.96B-0.24196,900 shs41,209 shs
10 Best Stocks to Own - Summer 2026 Cover
10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-0.53%+1.84%-0.75%+5.13%+29.67%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-0.53%+1.48%-3.51%+19.70%+65.18%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
-2.44%-2.36%+9.67%+23.05%+11.08%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
+3.09%-0.43%+14.29%+22.05%-6.41%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$253.26
+0.5%		$254.21
$186.05
▼
$282.15
$15.81B0.39679,422 shs75,525 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$80.84
-0.3%		$79.11
$47.26
▼
$93.42
$15.82B0.962.95 million shs272,101 shs
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$66.35
+2.0%		$60.85
$49.26
▼
$70.98
$12.84B0.242.07 million shs215,108 shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$11.67
-0.1%		$11.01
$6.28
▼
$12.58
$3.96B-0.24196,900 shs41,209 shs
10 Best Stocks to Own - Summer 2026 Cover
10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-0.53%+1.84%-0.75%+5.13%+29.67%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-0.53%+1.48%-3.51%+19.70%+65.18%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
-2.44%-2.36%+9.67%+23.05%+11.08%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
+3.09%-0.43%+14.29%+22.05%-6.41%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.05
Buy$300.3318.59% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.83
Moderate Buy$100.7924.68% Upside
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2.75
Moderate Buy$88.8333.87% Upside
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
2.75
Moderate Buy$20.4074.81% Upside

Current Analyst Ratings Breakdown

Latest TLX, BBIO, ASND, and BMRN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Hold (C-)
8/20/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/20/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$22.00
8/19/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$98.00
8/18/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$319.00
8/18/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$319.00
8/18/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/18/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$60.00 ➝ $59.00
8/17/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$82.00 ➝ $88.00
8/17/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$105.00 ➝ $111.00
8/14/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$280.00 ➝ $290.00
(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M19.39N/AN/A($2.97) per share-85.27
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M31.48N/AN/A($10.77) per share-7.51
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$3.22B3.99$2.84 per share23.38$31.68 per share2.09
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$803.79M4.93$0.04 per share268.72$1.23 per share9.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8919.6623.71N/A70.99%32.54%7.71%11/11/2026 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.57N/AN/AN/A-97.03%N/A-61.19%10/28/2026 (Estimated)
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$348.90M$0.37179.3212.290.482.14%5.32%3.69%10/26/2026 (Estimated)
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
-$7.12MN/AN/A194.50N/AN/AN/AN/AN/A

Latest TLX, BBIO, ASND, and BMRN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/10/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5756-$0.78-$0.2044-$0.78$220.91 million$243.68 million
8/6/2026Q2 2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$0.95$1.20+$0.25$0.23$932.03 million$989.71 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
N/AN/AN/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.23
1.17
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.56
2.39
1.32
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1.16
2.01
1.85

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
98.71%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.68%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400195.49 million167.67 millionOptionable
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
3,221193.57 million192.26 millionOptionable
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1,184339.78 millionN/AN/A

Recent News About These Companies

Telix Pharmaceuticals: Execution Is The Name Of The Game Here
August 24 at 7:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4939766-telix-pharmaceuticals-execution-is-the-name-of-the-game-here
Wedbush Reaffirms "Outperform" Rating for Telix Pharmaceuticals (NASDAQ:TLX)
August 22 at 2:18 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30975586
Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's What Happened
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telix-pharmaceuticals-nasdaqtlx-shares-gap-down-heres-what-happened-2026-08-21/
HotCopper highlights: Zip dominates investor attention as Telix, Liontown and American Tungsten trend
August 21, 2026  |  msn.comhttps://www.msn.com/en-au/money/top-stocks/hotcopper-highlights-zip-dominates-investor-attention-as-telix-liontown-and-american-tungsten-trend/ar-AA2aC3f9
Why were Telix shares just downgraded?
August 20, 2026  |  fool.com.auhttps://www.fool.com.au/2026/08/21/why-were-telix-shares-just-downgraded/
Telix Pharmaceuticals Limited (TLX) Stock: EBITDA Surges 146% as Revenue Hits $477M 
August 20, 2026  |  blockonomi.comhttps://blockonomi.com/telix-pharmaceuticals-limited-tlx-stock-ebitda-surges-146-as-revenue-hits-477m/
Telix Pharmaceuticals Limited: Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
August 20, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69361480-telix-pharmaceuticals-limited-telix-2026-half-year-results-strong-commercial-execution-and-momentum-in-late-stage-pipeline-399.htm
Telix Pharmaceuticals (NASDAQ:TLX) Receives "Outperform" Rating from Wedbush
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telix-pharmaceuticals-nasdaqtlx-receives-outperform-rating-from-wedbush-2026-08-20/
Telix Pharmaceuticals (NASDAQ:TLX) Announces Earnings Results
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telix-pharmaceuticals-nasdaqtlx-announces-earnings-results-2026-08-20/
Telix half-year revenue increases 22 per cent to 477 million dollars
August 20, 2026  |  vir.com.vnV
Telix Pharmaceuticals Limited (TLX) Q2 2026 Earnings Call Transcript
August 20, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4938549-telix-pharmaceuticals-limited-tlx-q2-2026-earnings-call-transcript
Telix Pharmaceuticals Limited 2026 Q2 - Results - Earnings Call Presentation
August 19, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4938545-telix-pharmaceuticals-limited-2026-q2-results-earnings-call-presentation
Telix Pharmaceuticals delivers robust half-year earnings and pipeline progress
August 19, 2026  |  msn.comhttps://www.msn.com/en-au/money/general/telix-pharmaceuticals-delivers-robust-half-year-earnings-and-pipeline-progress/ar-AA2avMqF
Telix Pharmaceuticals H1 Earnings Call Highlights
August 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telix-pharmaceuticals-h1-earnings-call-highlights-2026-08-19/
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
August 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/20/3348062/0/en/telix-2026-half-year-results-strong-commercial-execution-and-momentum-in-late-stage-pipeline.html
Telix Pharmaceuticals (NASDAQ:TLX) Trading Down 4.3% - Should You Sell?
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telix-pharmaceuticals-nasdaqtlx-trading-down-43-should-you-sell-2026-08-14/
Telix Pharmaceuticals (TLX) to Release Quarterly Earnings on Thursday
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telix-pharmaceuticals-tlx-to-release-quarterly-earnings-on-thursday-2026-08-13/
Telix Pharmaceuticals Ltd. ADR
August 12, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/tlx/financials/income/quarter
Hennion & Walsh Asset Management Inc. Takes Position in Telix Pharmaceuticals Limited $TLX
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hennion-walsh-asset-management-inc-takes-position-in-telix-pharmaceuticals-limited-tlx-2026-08-12/
Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
August 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telix-pharmaceuticals-limited-nasdaqtlx-receives-consensus-recommendation-of-moderate-buy-from-analysts-2026-08-09/
Telix to host R&D Day in New York on 22 September
August 6, 2026  |  msn.comhttps://www.msn.com/en-sg/money/general/telix-to-host-r-d-day-in-new-york-on-22-september/ar-AA29uJuw

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$253.26 +1.31 (+0.52%)
As of 11:32 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$80.84 -0.23 (-0.28%)
As of 11:32 AM Eastern
This is a fair market value price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BioMarin Pharmaceutical stock logo

BioMarin Pharmaceutical NASDAQ:BMRN

$66.35 +1.28 (+1.97%)
As of 11:32 AM Eastern
This is a fair market value price provided by Massive. Learn more.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Telix Pharmaceuticals stock logo

Telix Pharmaceuticals NASDAQ:TLX

$11.67 -0.01 (-0.09%)
As of 11:31 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas